

ANTARES PHARMA, INC.  
Form 4  
June 25, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**HOBBS EAMONN P**

(Last) (First) (Middle)

**C/O ANTARES PHARMA,  
INC., 100 PRINCETON SOUTH,  
SUITE 300**

(Street)

**EWING, NJ 08628**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

**ANTARES PHARMA, INC. [ATRS]**

3. Date of Earliest Transaction  
(Month/Day/Year)

**06/23/2014**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**President and CEO**

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |
| Common Stock                    | 06/23/2014                           |  | A                              |   | 182,724<br>(1)  | A  | (2) 282,084 D                     |
| Common Stock                    | 06/23/2014                           |  | A                              |   | 91,362<br>(3)   | A  | (2) 373,446 D                     |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

Edgar Filing: ANTARES PHARMA, INC. - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount or Number of Shares                              |
| Stock option (right to buy)                | \$ 3.01  | 06/23/2014                           |  | A                              | 340,502<br>(4)  | (5) 06/22/2024   | Common Stock 340,502  |
| Stock option (right to buy)                | \$ 3.01  | 06/23/2014                           |  | A                              | 159,498<br>(6)  | (5) 06/22/2024   | Common Stock 159,498  |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                   |       |
|---|---------------|-----------|-------------------|-------|
|   | Director      | 10% Owner | Officer           | Other |
| HOBBS EAMONN P<br>C/O ANTARES PHARMA, INC.<br>100 PRINCETON SOUTH, SUITE 300<br>EWING, NJ 08628 | X             |           | President and CEO |       |

## Signatures

Robert F. Apple as attorney-in-fact for Eamonn P. Hobbs  
Date: 06/25/2014

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the target number of shares Mr. Hobbs may receive pursuant to the terms of the performance stock unit award made to Mr. Hobbs under the 2008 Equity Compensation Plan if certain performance goals are attained over the performance period specified in the award agreement evidencing the performance stock unit award and Mr. Hobbs continues in employment with the Company through that period.
- (2) Not applicable
- (3) Represents grants of shares of restricted Common Stock issued under the 2008 Equity Compensation Plan pursuant to Mr. Hobbs' employment agreement dated June 23, 2014. The shares vest in three equal annual installments.
- (4) Represents grant of options to purchase shares of common stock, par value \$0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted as a sign-on bonus pursuant to Mr. Hobbs' employment agreement dated June 23, 2014.

## Edgar Filing: ANTARES PHARMA, INC. - Form 4

- (5) The options vest in equal quarterly installments over three years.
- (6) Represents grant of options to purchase shares of common stock, par value \$0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted pursuant to Mr. Hobbs' employment agreement dated June 23, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.